Avecho Biotechnology Ltd has released a press release.
Improved Propofol TPM Formulation Passes Toxicology Study
Filed with ASX ·
6ix hasn’t read this filing yet.
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- September 2020 Quarterly Activities Report & Appendix 4C
- TPM Cannabinoid Development Program Update
- Progress Update for TPM Cannabinoid Development Program
- June 2020 Quarterly Activities Report & Appendix 4C
- March 2020 Quarterly Activities Report & Appendix 4C
Later from Avecho Biotechnology
- AVE begins Human Trial on CBD product
- December 2020 Quarterly Activities Report & Appendix 4C
- AVE receives firm commitment to raise $5.06 via placement
- Avecho receives ethics approval for CBD human trial
- March 2021 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology